Octreotide-Treated Diabetes Accompanied by Endogenous Hyperinsulinemic Hypoglycemia and Protein-Losing Gastroenteropathy
Figure 5
Representative blood glucose profiles after the treatment of octreotide LAR for 4 months. Blood glucose profile and the dose of each insulin injection are shown (a). The duration between ticks on the X-axis represents 24 h. The frequency of hypoglycemia, defined as below 70 mg/dL of blood glucose, is shown (b).
